Apexigen Announces New Data from Phase 1/2 Trial
https://finance.yahoo.com/news/apexigen-announces-data-phase-1-130000869.html
Luminopia Announces Oversubscribed Seed Extension Round
https://www.businesswire.com/news/home/20221111005154/en/Luminopia-Inc.-Announces-Oversubscribed-Seed-Extension-Financing-Round?
Apexigen Publicly Listed Post-Business Combination
https://www.globenewswire.com/news-release/2022/08/01/2489330/0/en/Apexigen-Completes-Business-Combination-to-Become-a-Publicly-Listed-Im...
Skyhawk Collaboration with Sanofi
https://www.prnewswire.com/news-releases/skyhawk-announces-collaboration-agreement-with-sanofi-for-oncology-and-immunology-targets-301580...
GrowthCap Top 25 Healthcare Investors - William Dai
https://www.businesswire.com/news/home/20220428005018/en/ShangBay-Capital%E2%80%99s-William-Dai-Named-to-GrowthCap%E2%80%99s-2022-Top-25-...
William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022
The Top 25 Healthcare Investors of 2022 | GrowthCap (growthcapadvisory.com) Congrats William!
Apexigen to go public via SPAC merger
Apexigen has announced a SPAC merger with Brookline Capital Acquisition Corporation to help advance its multiple clinical trials....
Huma.AI Series A & Product Update
Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform | Business Wire
2022 SVB Report Results
We are proud to announce that ShangBay Capital is once again ranked #1 again as the Most Active New Device Investor both in the U.S. and...
Robert Kamen joins ShangBay Capital as our newest Senior Advisor
https://www.businesswire.com/news/home/20211102005148/en/Robert-Kamen-Ph.D.-Joins-ShangBay-Capital-as-a-Senior-Advisor
